SHetA2, a New Cancer-Preventive Drug Candidate by Liu, Shengquan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
SHetA2, a New Cancer-Preventive Drug Candidate
Shengquan Liu, Guangyan Zhou,
Sze Ngong Henry Lo, Maggie Louie and
Vanishree Rajagopalan
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/65365
Provisional chapter
SHetA2, a New Cancer-Preventive Drug Candidate
Shengquan Liu, Guangyan Zhou,
Sze Ngong Henry Lo, Maggie Louie and
Vanishree Rajagopalan
Additional information is available at the end of the chapter
Abstract
SHetA2 (NSC 721689) is a novel synthetic flexible heteroarotinoid that has promising
cancer-preventive activity, and has exhibited growth inhibition on 60 cancer cell lines
in vitro, along with ovarian, lung, and kidney cancers in vivo. It binds and interferes
with the function of a molecular chaperone, mortalin, leading to mitochondrial swelling
and mitophagy that induce apoptosis in cancer cells without harming normal cells. It
showed minimal toxicity in preclinical studies and thus is now in Phase-0 clinical trial.
This  chapter  summarizes  its  evolution,  synthesis,  structure-activity  relationship,
mechanism of action, pharmacokinetics, and potential clinical applications in last 12
years. It also provides insights into designing more potent and safer SHetA2 analogs
for future cancer-preventive drug development.
Keywords: SHetA2, flexible heteroarotinoids, apoptosis, cancer prevention, ovarian
cancer
1. Introduction
Cancer-preventive agents are biologics, dietary supplements, nutrients or marketed drugs
used to reduce the risk of developing cancer or prevent the recurrence of cancer [1]. The
cancer-preventive actions of these agents are mediated by a variety of proposed mechanisms,
which include inhibition of oxidative and inflammatory stress, immunomodulatory action,
induction of cell differentiation and apoptosis, and inhibition of cell growth and angiogenesis.
Hundreds of natural and synthetic compounds have been shown to inhibit cancer cell growth
including vitamins (vitamins A, D, and E), organosulfur compounds (brassinin, sulforaphane,
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and  isothiocyanates),  minerals  (calcium  and  selenium),  phytoestrogens  (resveratrol),
flavonoids  (genistein  and  quercetin),  synthetic  compounds  (retinoids,  sulforamate,  and
prenylated flavonoid analogs) [2], and marketed drugs (tamoxifen, raloxifene, finasteride,
aspirin, sulindac, difluoromethylornithine, and metformin) [3]. Drug development for cancer
prevention imposes distinct challenges beyond those associated with drug development for
cancer therapy. One of the challenges is that cancer preventive agents must have higher
therapeutic index. Nevertheless, the potential to intervene prior to the cancer developing is
an attractive strategy to fight cancers [4].
A novel class of anticancer agents that has demonstrated such qualities is the flexible
heteroarotinoids (Flex-Hets). Flex-Hets, derived from the retinoids, have exhibited potential
anticancer activities in various cancer cell lines, while displaying minimal toxicity to normal
cells. Among these compounds, SHetA2 [(4-nitrophenyl)amino][2,2,4,4-tetramethylthiochro-
man-6-yl]amino]methane-thione) exhibited the greatest growth inhibitory efficacy and
potency against various cancer cell lines and was chosen as a lead compound for further
development [5–7]. SHetA2 has been shown to interfere with mortalin binding to p53 and
p66 Src homologous-collagen homologue (p66shc) leading to apoptosis in cancer cells [8].
Furthermore, it has been shown to induce both intrinsic [9] and extrinsic apoptotic pathway
[10], cause cell cycle arrest [11], induce differentiation [7], and inhibit angiogenesis [12] in
cancer cells, while displaying negligible toxicity in animal models [13]. Hence, SHetA2 was
regarded as a novel class of promising anticancer agent that selectively targeted the cancer
cells. Consequently, it was evaluated in preclinical development for cancer prevention
through the National Cancer Institute (NCI) Rapid Access to Intervention Development
(RAID) and Rapid Access to Preventive Intervention Development (RAPID) program [6].
Studies in rats and dogs showed that no toxicity was observed in any of the tested dosage
groups. The no-observed-adverse-effect-level (NOAEL) for SHetA2 was not established and
was considered to be above 1500 mg/kg/day in dogs [13]. The therapeutic window for
administrative safety with SHetA2 was determined to be 25- to 150-folds above in vivo
effective doses. As a result, it is currently undergoing Phase-0 clinical trials through RAID
[14]. This chapter will provide a comprehensive review of SHetA2, including its design and
development, and possible molecular targets and mechanisms of action and its potential
clinical applications, based on the literature published thus far.
2. History of retinoid development
2.1. Retinoids
Retinoids, including natural retinoic acid (RA) and its synthetic derivatives, are a group of
promising anticancer agents that have shown both chemotherapeutic and chemopreventive
potential in both animals and humans [15–17]. They exhibit therapeutic properties by activat-
ing the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs) [18]. Each receptor
has three subtypes (-α, -β, -γ), and they belong to a family of proteins that regulate the
transcription of genes responsible for a variety of metabolic, developmental, and differentia-
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tion pathways in cells and tissues [19]. Retinoids have been shown to inhibit growth, and
induce differentiation and apoptosis of cancer cells both in vitro and in vivo [20, 21]. Naturally
occurring retinoids, all-trans-retinoic acid (ATRA, Figure 1, 1), 9-cis-retinoic acid (Figure 1, 2),
and 13-cis-retinoic acid (Figure 1, 3) have been shown to display significant anticancer
activities [22]. Synthetic retinoids, such as N-(4-hydroxyphenyl) retinamide (4HPR, fenreti-
nide, Figure 1, 4), are also effective inducers of apoptosis [23]. However, the use of retinoids
as chemotherapeutics has been hampered by their local and systemic toxicities and side effects.
Chronic retinoid treatment can lead to teratogenicity and toxicities to the skin, mucus mem-
branes, hair, eyes, gastrointestinal system, liver, endocrine system, kidneys, and bone [24].
These toxicities are found to be associated with the activation of the nuclear retinoid receptors
[25, 26].
Figure 1. Chemical structures of retinoids, heteroarotinoids, and flexible-heteroarotinoids.
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2.2. Arotinoids
Recognizing the potential chemopreventive and chemotherapeutic effects of retinoids,
chemists have tried to design and synthesize new retinoid derivatives that express high
cytotoxic potential with lower toxicity. The rationale is that by developing compounds that
selectively activate only one retinoid receptor subtype, the associated toxicities could be
reduced. For example, RXR-selective compounds were thought to have great potential for
pharmacological use against tumors and other diseases due to a large number of ligand
activated receptors whose activities involve dimerization with RXR receptors [19]. Bexarotene
(Targretin®, with a one-carbon linker), is a selective RXR agonist and the first synthetic
arotinoid approved for the treatment of all stages of cutaneous T-cell lymphoma [27]. RARγ,
selectively expressed at high levels in the skin, has been shown to be the mediator of retinoid
activity [28]. Early efforts to increase the therapeutic ratio of retinoids included increasing the
structure rigidity by incorporating a double-bond between the two aromatic rings, leading to
the development of arotinoids with two atom linker. For example, TTNPB (Figure 1, 5), an
arotinoid with significant anti-tumor activity [29] was found to be selective for RAR receptors
[30]. Unfortunately, intolerable toxicities observed in animal models limited its clinical utility
[29].
2.3. Heteroarotinoids
Subsequent structural modifications involved the addition of one heteroatom (O, N, and S) in
the cyclic ring of the arotinoids to block its oxidation into toxic metabolites. This resulted in
the development of a new class of compounds called the heteroarotinoids (Hets, Figure 1, 6–
12). These Hets exhibited similar biological activities to retinoids, but with significantly
reduced toxicities [29, 31].
2.4. Flexible heteroarotinoids
Different linkers were placed between the two aryl groups of the Hets to increase their rigidity,
providing a more specific fit into each receptor’s binding pocket. Two-atom linkers, such as
amide (Figure 1, 8) and esters (Figure 1, 9–11) were synthesized, and they showed varying
degree of receptor selectivity. Interestingly, Hets with either the three-atom urea (Figure 1, 14,
17, 18) or thiourea (Figure 1, 15, 16, 19, 20) linker demonstrated significant anticancer activity
without activating any of the retinoid receptors [6]. These compounds showed significant
growth inhibitory activities against the ovarian cancer cell lines: Caov-3, OVCAR-3, and SK-
OV-3, while exhibiting low activities against normal and benign cells. Moreover, due to the
lack of RAR/RXR activation, these compounds did not exhibit the associated toxicities observed
with other retinoids. Among these compounds, SHetA2 (Figure 1, 16) demonstrated the
greatest potency against the aforementioned ovarian cancer cell lines at concentrations ranging
from 0.2–3.7 μM. Since both urea and thiourea linkers are somewhat flexible in nature, these
compounds were termed flexible heteroarotinoids (Flex-Hets). The evolution of SHetA2 is
shown in Figure 2.
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Figure 2. The evolution of SHetA2 from all trans retinoic acid (ATRA).
3. SHetA2, a Flex-Het
Flex-Hets have shown cancer-preventive activity by regulating apoptosis, cell growth, and
differentiation in multiple types of cancer cell lines. They display significantly greater growth
inhibition activities against ovarian cancer cells than both normal and benign ovarian cells [6].
Among the Flex-Hets, SHetA2 has shown to induce the highest levels of apoptosis in multiple
cancer cell types, while retaining the differential resistance in normal cells [5]. SHetA2
functions independently of retinoid receptors [32] and therefore, lacks the toxicities associated
with conventional retinoids. More importantly, SHetA2 differentially induces apoptosis in
cancer cells while sparing normal cells [6]. All 60 cancer cell lines in NCI human tumor panel
were sensitive to the growth inhibition activities of SHetA2 at micromolar concentrations [5]
(Table 1). Despite this wide range of activity against cancer cells, normal and benign human
ovarian, endometrial, and oral cultures were resistant to SHetA2-induced apoptosis and
growth inhibition [6, 9]. In a recent study, SHetA2 was tested to be negative across three genetic
toxicology assays, namely the in vitro Salmonella-Escherichia coli mutagenicity assay, Chinese
hamster ovary cell chromosome aberration assay (CHO-CA), and in vivo mouse bone marrow
micronucleus assay [34]. These assays are recommended by the International Conference on
Harmonization (ICH), US Food and Drug Administration (FDA), and other regulatory
agencies for the detection of mutagenicity by chemicals [35]. These negative results showed
that SHetA2 was neither mutagenic nor genotoxic. In addition, SHetA2 exhibited no evidence
of toxicity in animal models including dogs [13], and it did not induce skin irritation or
teratogenicity [5, 36]. Encouraged by these promising results, SHetA2 was evaluated by NCI’s
RAID program for preclinical development as a cancer therapeutic agent (Application 196,
Compound NSC 726189), and by RAPID program as a chemopreventive agent. Since SHetA2
showed no toxicity in preclinical studies, it is now in Phase-0 clinical trial.
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GI50 Mean Graph for SHetA2 (NSC 726189) [33]
Cancer panel Cell line Log GI50 (SHetA2) Log GI50 (ATRA)
Leukemia CCRF-CEM −4.9 −4.2
HL-60(TB) −4.5 −4.7
K-562 −5.0 −4.3
MOLT-4 −4.7 −4.3
RPMI-8226 −4.5 −5.7
SR −4.9 −4.2
Nonsmall-cell lung carcinoma A549/ATCC −4.9 −4.3
EKVX −4.9 −4.0
HOP-62 −4.7 −4.2
HOP-92 −4.7 −4.0
NCI-H226 −4.9 −4.3
NCI-H23 −4.9 −4.2
NCI-H322M −5.0 −4.0
NCI-H460 −4.6 −4.2
NCI-H522 −5.0 −4.2
Colon cancer COLO 205 −4.9 −4.2
HCC-2998 −5.4 −4.2
HCT-116 −4.8 −4.2
HCT-15 −4.9 −4.2
HT29 −4.6 −4.2
KM12 −5.0 −4.3
SW-620 −4.8 −4.2
CNS (gliomas) SF-268 −4.6 −4.0
SF-295 −5.0 −4.2
SF-539 −5.0 −4.2
SNB-19 −4.7 −4.2
SNB-75 −4.8 −4.0
U251 −5.0 −4.2
Melanoma LOX IMVI −4.9 −4.4
MALME-3M −5.6 −4.3
M14 −4.7 −4.2
MDA-MB-435 −4.9 −4.2
SK-MEL-2 −5.0 −4.4
SK-MEL-28 −4.8 −4.2
SK-MEL-5 −5.0 −4.2
UACC-257 −4.9 −4.2
UACC-62 −5.0 −4.0
Ovarian cancer IGROV1 −5.0 −4.0
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OVCAR-3 −5.0 −4.2
OVCAR-4 −4.8 −4.0
OVCAR-5 −4.8 −4.0
OVCAR-8 −4.8 −4.2
NCI/ACR-RES −4.9 −4.4
SK-OV-3 −4.8 −4.0
Renal cancer 786-0 −4.8 −4.2
A498 −5.0 −4.0
ACHN −5.0 −4.2
CAKI-1 −4.9 −4.2
RXF 393 −4.7 −4.0
SN12C −5.0 −4.2
TK-10 −5.0 −4.1
UO-31 −4.9 −4.0
Prostate cancer PC-3 −4.0 −4.3
DU-145 −4.9 −4.2
Breast cancer MCF7 −4.5 −4.4
MDA-MB-231 −5.0 −4.3
HS 578T −4.6 −4.0
BT-549 −4.9 −4.2
T-47D −4.8 −6.3
Lower values indicate greater inhibition of cell growth.
Table 1. Growth inhibition values (GI50) of NCI’s human tumor cell line panel expressed in log scale.
4. Synthesis of SHetA2
The synthesis of SHetA2 mainly involved the preparation of the intermediate, aminothiochro-
man (Figures 3 and 4). Early synthetic procedure (Figure 3) involved using Fe/HOAc to reduce
the nitro group with a yield of 40% [6]. The nitration reaction was the problematic step with
only a 26% yield, since many additional by-products were formed in this reaction. In order to
address this issue, Tallent et al. employed a nitrogen-containing starting material (4-acetami-
dobenzenethiol) [37] (Figure 4). They used methyllithium instead of methylmagnesium
bromide to form the intermediate carbinol. In the cyclization procedure to form the thiochro-
man, chlorobenzene was used as solvent with a 58% yield avoiding the use of flammable and
noxious CS2. This method circumvented the low-yielding nitration step and the subsequent
reduction step to generate the amine group of aminothiochroman. The improved synthesis
was shorter and afforded a 5-fold higher overall yield. The final product, SHetA2, was formed
by reacting the aminothiochroman with 4-nitrophenyl isothiocyanate in tetrahydrofuran
(Figure 4).
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Figure 3. Synthesis of aminothiochroman.
Figure 4. Improved synthesis of aminothiochroman and SHetA2.
5. Structure-activity relationship
Structure-activity relationship (SAR) of SHetA2 and its derivatives has been valuable to
identify important structural modifications that have contributed to its anticancer potency and
selectivity, and to guide the design of more potent and less toxic SHetA2 analogs. Figure 2
illustrates the structural evolution of SHetA2 from ATRA. The goal was to increase the
selectivity of retinoids towards RAR/RXR subtypes, so as to reduce the associated toxicities
while retaining its anticancer activities. It has been shown that RAR-specific ligands can rescue
Raldh2−/− embryos as effectively as ATRA, whereas RXR ligand showed no effect [36]. One
strategy was to conformationally restrict the double-bonds of RA to allow a better fit into a
specific receptor subtype by incorporating aromatic rings. For example, SR3986 (Figure 2) was
developed with an aromatic ring from ATRA. Subsequently, TTNPB (5), the lead arotinoid,
was modified with a diaryl group to increase its rigidity, and it was found to be selective for
RAR receptors and 10 times more potent as compared to ATRA [38]. Unfortunately, this
compound also exhibited a 10,000-fold increase in toxicity, which limited its clinical usage [29].
In order to reduce toxicity, a benzylic carbon in the tetrahydronaphthalene was replaced with
a heteroatom (O, N, and S). The purpose was to prevent benzylic (metabolic) oxidation which
could result in toxic metabolites. This single modification resulted in Hets (Figure 1, 6–12) with
similar biological activities to RA but significantly reduced toxicities [29, 31]. An example was
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the diaryl heteroarotinoid (Figure 1, 6), a RAR-selective retinoid derivative. It differed from
TTNPB by an oxygen heteroatom, but exhibited a significant decrease in toxicity, increasing
the maximum tolerated dose (MTD) by 3000-fold as compared to TTNPB (Figure 1, 5) [39].
Other monoaryl heteroarotinods (Figure 1, 7a, 7b) were also evaluated, and revealed a 3-fold
decrease in toxicity along with a decreased ability to activate the RAR receptors when
compared to ATRA (Figure 5) [40, 30].
Figure 5. Maximum tolerated dose (MTD) for retinoids and their derivatives.
5.1. Thiochroman rings
SAR studies have identified structures containing six-membered ring (Figure 1, 7a, 7b) tend
to confer increased RARβ selectivity over five-membered ring systems (Figure 1, 12a, 12b),
while sulfur heteroatom confers a greater RARγ selectivity over oxygen atom [19]. The
thiochroman ring system is flexible and has been shown to induce apoptosis to a greater extent
than a rigid planar quinoline unit [41]. These findings highlight the important role played by
SHetA2, a New Cancer-Preventive Drug Candidate
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the thiochroman ring in enhancing the activity of Flex-Hets. Therefore, the thiochroman ring
forms one of the fundamental moieties of SHetA2 and its analogs (14–20).
5.2. Two-atom linkers
To further increase the selectivity for each RAR and RXR receptors, various linkers were placed
between the two aryl groups of the Hets by modifying their structure rigidity. Two-atom linker
compounds such as amide (Figure 1, 8) and ester (Figure 1, 9) were reported [42, 43]. Com-
pound (8) was found to be a receptor panagonist, while compound (9) was RXR selective. Both
showed significant growth inhibitory activities against head and neck cancer using a tumor
xenograft mouse model [42]; however, only compound (8) induced apoptosis in ovarian cancer
cells. This indicated that RXR activation is sufficient to inhibit tumor growth, while activation
of both RAR and RXR are required for the maximum activity, at the expense of toxicity. Other
two ester-linked compounds (Figure 1, 10, 11) were found to activate both RARs and RXRs [44].
On the other hand, these ester-linked Hets appeared to only induce growth inhibition but not
apoptosis.
5.3. Three-atom linkers
Three-atom linkers have also been reported in the literature (Figure 4, 21, 22). It was suggested
that the presence of a three-atom linker may increase RAR selectivity [45], and the ability for
linkers to form hydrogen bonds may enhance RARγ selectivity [46]. As such, a series of urea/
thiourea derivatives were synthesized and evaluated (Figure 1, 14–20) [6, 7]. Unlike conven-
tional retinoids, these Flex-Hets were able to induce selective and potent apoptotic activity in
cancer cells independent of RAR/RXR activation [44]. The only retinoid activity retained by
Flex-Hets is the ability to induce differentiation and reverse the cancerous phenotype.
The X-ray crystal structure of the Flex-Hets showed that a unique lattice network formed
through extensive intermolecular H-bonding between the NH and the oxygen of the highly
polarized C=O urea linker in another molecule, whereas this was not observed in the C=S
thiourea derivatives. It suggested that the urea derivatives may be more active than its thiourea
counterpart. This observation is also supported by their in vitro growth inhibition activities
where the urea derivative, SHetC2 (17), demonstrated to be slightly more potent (EC50= 1.02
μM) than its thiourea counterpart, SHetA2 (16) (EC50= 1.72 μM) [41].
Regardless, the fact remains that millions of dollars have been invested by the NCI RAID and
RAPID programs in the preclinical development of SHetA2, and many studies involving
animal models have shown that SHetA2 is a potent and selective inducer of apoptosis with no
significant toxicities. While SHetC2 lacks these extensive studies, it does show potential as the
next chemopreventive drug candidate following SHetA2. These results indicate that the
inclusion of three-atom urea/thiourea linker is critical to induce potent anticancer activities
independent of RAR/RXR activation as observed in these Flex-Hets. Tables 2 and 3 summarize
the effects of the structural modifications on the growth inhibition by these derivatives against
various cancer cell lines reported to-date.
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Compound Cell growth inhibition
Renal (%) Ovarian
cancer (%)
NE
EC50
(µM)
Vulvar
cancer
(%) 
Cervical cancer
(%) 
HN cancer
(%)Cancer Normal 
1 1 1 2 3 NE 1 2 1 2 3 4 1 2
 
– – – – – – – – – – – – 19 18
– – – – – – – – – – – – 15 12
– – – – – – – – – – – – 64 37
– – 0 – 1 – 34 14 40 25 – – 12 13
– – 5 – 0 – 81 84 26 16 – – 9 7
– – 6 – 2 – 47 25 25 13 – – 5 15
6.5 16 – – – – – – – – – – – 52
– – 25 – 31 >10 38 31 24 28 45 47 – 51
– – 62 43 65 >10 – – – – – – – 74
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Compound Cell growth inhibition
Renal (%) Ovarian
cancer (%)
NE
EC50
(µM)
Vulvar
cancer
(%) 
Cervical cancer
(%) 
HN cancer
(%)Cancer Normal 
– – 11 – 19 – 34 19 – – – – 74 –
Growth inhibition (%) for renal cancer cell lines (1) Caki-1 and (2) 786-0; Normal renal cells (1) HK-2 and (2) RTC91696
[23]. Growth Inhibition (%) for ovarian cancer cell lines (1) CAOV-3, (2) OVCAR-3, and (3) SKOV-3 [6]. EC50 values for
50% growth inhibition for ovarian cancer cell line (4) A2780, and Normal endometrial cells (NE) [6, 41]. Growth
inhibition (%) for cervical cancer cell lines (1) SiHa, (2) CC-1, (3) C33a, and (4) HT-3 [5]. Growth inhibition (%) for head
and neck squamous cell cancer cell lines (HN) (1) SCC-2 [43], and (2) SCC-38 [32, 42]. Growth inhibition (%) for vulvar
cancer cell lines (1) SW954 and (2) SW962 from Ref. [43].
“–” indicates no data available.
Table 2. Structural modifications of Hets, and their effects on cancer cell growth.
 
Cell growth inhibition
Renal
cancer
(%)
Renal
normal
(%)
Ovarian
cancer (%)
NE Cervical
cancer (%)
HN
cancer (%)
EC50(µM)
X R1 R2 R3 1 2 1 2 1 2 3 4 NE 1 2 3 4 1
14 O CO2Et H H 69 45 26 40 40 69 47 2.8 4.5 67 59 85 76 42
15 S CO2Et H H 56 54 35 28 24 58 42 2.9 2.7 58 42 84 65 39
16 S NO2 H H 84 72 51 37 55 67 45 1.7 3.0 68 58 87 92 81
17 O NO2 H H 86 79 53 52 – – – 1.0 2.3 – – – – –
18 O CO2Me H H 57 62 26 46 – – – – – – – – – –
19 S CO2Me H H 39 45 44 38 – – – – – – – – – –
20 S H CO2Me H 34 42 48 – – – – – – – – – – –
SHetA19 S NO2 H Me – – – – 32 65 51 – – – – – – 68
Growth inhibition (%) for renal cancer cell lines (1) Caki-1 and (2) 786-0; Normal renal cells (1) HK-2 and (2) RTC91696
[23]. Growth Inhibition (%) for ovarian cancer cell lines (1) CAOV-3, (2) OVCAR-3, and (3) SKOV-3 [6]. EC50 values for
50% growth inhibition for ovarian cancer cell line (4) A2780, and Normal endometrial cells (NE) [6, 41]. Growth
inhibition (%) for cervical cancer cell lines (1) SiHa, (2) CC-1, (3) C33a, and (4) HT-3 [5]. Growth inhibition (%) for head
and neck squamous cell cancer cell lines (HN) (1) SCC-2 [43], and (2) SCC-38 [32, 42]. Growth inhibition (%) for vulvar
cancer cell lines (1) SW954 and (2) SW962 from Ref. [43].
“–” indicates no data available.
Table 3. Structural modifications of Flex-Hets, and their effects on cancer cell growth.
Substitutions on the phenyl group have also been evaluated [7]. The nitro (NO2) substitution
(Table 3, 16, 17) consistently exhibited greater growth inhibitory and apoptotic activity than
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their methyl (Table 3, 18–20) or ethyl ester counterparts (Table 3, 14, 15). This suggests that
the nitro substitution may have enhanced the overall activity of the compound. Collectively,
for the Flex-Hets, the thiochroman ring and nitro substitution are important for enhancing the
anticancer activity, while the thiourea linker is crucial for RAR/RXR independent and selective
anticancer activities against cancer cells.
5.4. Three-atom linker with thiochroman ring replaced
In order to expand the potential clinical applications, we designed, synthesized, and evaluat-
ed nine p-nitrodiarylthiourea analogs in breast (MCF-7, T-47D, MDA-MB-453) and prostate
(DU-145, PC-3, LNCaP) cancer cell lines for their anticancer activities. Majority of our com-
pounds were able to inhibit the growth of these six cancer cell lines at low micromolar
concentrations. Compound 23 (Figure 6) was found to be the most potent anticancer agent in
this series with GI50 values of 3.16 μM for MCF-7, 2.53 μM for T-47D, 4.77 μM for MDA-MB-453
breast cancer lines and 3.54 μM for LNCaP prostate cancer cell line. These GI50 values were
comparable to the parent compound, SHetA2 [47].
Figure 6. Three- and four-atom linkers in retinoid derivatives.
5.5. Four-atom linker
Another approach to the structure modification of SHetA2 was to keep the thiochroman ring
but replace the thiourea linker with a 4-atom acrylamide linker NC(O)C=C and various
substitutions on the terminal aryl ring. When evaluated in a cytotoxicity assay of the human
A2780 ovarian cancer cell line, results indicate that activity of 4-nitro phenyl analogs are
comparable to that of SHetA2 with efficacies slightly reduced compared to SHetA2 [48]. The
α,β-unsaturated acrylamide may contribute to its increase in potency and the compound 24
(Figure 6) is the example.
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6. Mechanism of action
The biological targets and SHetA2’s mechanism of action have been extensively studied.
Coimmunoprecipitation experiments demonstrated that SHetA2 interfered with the binding
of mortalin, a molecular chaperone to p53 and p66 Src homologous-collagen homolog (p66shc)
in A2780 ovarian cancer cell line, leading to mitochondrial swelling and mitophagy and finally
apoptosis [8]. SHetA2 is also involved in modulating other cellular processes including cell-
growth, differentiation, and angiogenesis.
6.1. Induction of apoptosis
6.1.1. Intrinsic pathway
SHetA2 is shown to selectively induce apoptosis in various cancer cell lines by targeting the
mitochondria [32]. Exposure of SHetA2 to squamous carcinoma cells resulted in a decrease in
mitochondrial permeability transition, followed by the release of cytochrome c into the
cytoplasm, activation of caspase-3, and the induction of intrinsic apoptotic pathway. Further
studies proposed that SHetA2-mediated mitochondrial swelling involved lowering the levels
of anti-apoptotic proteins such as Bcl-XL and Bcl-2 in A2780 ovarian cancer cell [9]. However,
the pro-apoptotic Bax expression was unaffected by SHetA2, suggesting SHetA2 may regulate
the levels of Bcl-2 to promote apoptosis [9]. On the other hand, exposure of SHetA2 to normal
ovarian or endometrial cells was found to increase both Bcl-XL and Bcl-2 protein levels. The
up-regulation of these anti-apoptotic proteins may provide the cytoprotective effects necessary
to block SHetA2-induced apoptosis in normal cells [9].
Figure 7. Pathways involving SHetA2-induced apoptosis.
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6.1.2. Extrinsic pathway (death receptor pathway)
Exposure of non-small cell lung cancer cells (NSCLC) to SHetA2 revealed the induction of the
extrinsic apoptotic pathway involving the death receptor 5 (DR5) [49]. It was shown that
SHetA2-enhanced DR5 expression through the enhanced binding of CAAT/enhancer-binding
protein homologous protein (CHOP) to its binding site located in the 5’-flanking region of the
DR5 gene. Since CHOP is highly inducible during endoplasmic reticulum (ER) stress, this
finding suggests that SHetA2 may act as an inducer of ER stress. The induction of DR5
expression leads to caspase 8-dependent apoptosis. Moreover, the induction of DR5 was shown
to enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apop-
tosis (Figure 7). Further studies found that down-regulation of cellular FLICE-inhibitory
protein (c-FLIP), and to a lesser extent of survivin, were involved in SHetA2-induced apoptosis,
as well as enhancement of TRAIL-initiated apoptosis [50]. c-FLIP is a major inhibitor of the
extrinsic apoptotic pathway [51], while survivin modulates both intrinsic and extrinsic
apoptotic pathways [52].
Figure 8. Working model for the apoptotic pathway involving NF-kB in ovarian cancer cells.
TRAIL and its receptors have also attracted much attention recently because TRAIL preferen-
tially induces apoptosis in malignant cells while sparing most normal cells [53]. SHetA2 was
found to sensitize ovarian carcinomas that are resistant to these DR ligands, without harming
the normal cells [54, 55]. This suggests a possible synergistic effect Further investigation
identified that downregulation of NF-kB transactivation activity by SHetA2 was involved in
this sensitizing effect, triggering extrinsic apoptosis in cancer cells resistant to certain chemo-
therapeutics [55]. SHetA2 was shown to repress the upstream IkB kinase (IKK) activity that
resulted in NF-kB downregulation. Apart from DR ligands, SHetA2 has also shown its
chemosensitizing effects against cisplatin-resistant ovarian cancer through p53-independent
pathways [6, 56]. However, such enhancement of sensitivities was not observed in resistant
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uterine cancer cell lines for a number of chemotherapeutics in combination with SHetA2
treatment (Figure 8) [57].
Apoptotic pathways affected by SHetA2
Possible biological targets Effect Reference
Intrinsic ↓ GSH Redox regulation [7]
↓ Bcl-2 Antiapoptotic [9]
↓ Bcl-XL Antiapoptotic [9]
↓ Survivin Antiapoptotic [50]
↑ Caspase-9 Proapoptotic [49]
↑ Caspase-3 Proapoptotic [32]
↑ Bid Proapoptotic [49]
Extrinsic ↑ Caspase-8 Proapoptotic [10]
↑ Bip/GRP78, IRE1α, ATF4, XBP1 ER stress [49]
↑ DR-5 Cell death [55]
↑ CHOP Cell death [49]
↓ IKK Cell survival [55]
↓ NF-kB Cell survival [50]
↓ c-FLIP Antiapoptotic [50]
Cell cycle pathways
↓ Cyclin D1 G1 arrest [11]
↓ AP-1 Cell-cycle progression [62]
Differentiation induction pathways
↑ E-Cadherin Differentiation [7]
↑ MUC1 Differentiation [44]
Antiangiogenic pathways
↑ Thrombospondin (TSP-4) Antiangiogenic [12]
↓ Thymidine Phosphorylase (TP) Angiogenic [12]
↓ VEGF Angiogenic [12]
Signal transduction pathways
↓ KIT kinase (c-KIT) Cell death [63]
Table 4. Possible biological pathways affected by SHetA2 and its anticancer activities.
6.1.3. ROS and GSH
Increased reactive oxygen species (ROS) level was initially thought to be responsible for
SHetA2-induced apoptosis. Multiple studies have documented the ROS generation along with
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mitochondrial swelling and the release of cytochrome c in various cancer cell lines [6, 32].
Studies have also shown that SHetA2 is able to form adducts with glutathione (GSH) [7, 58].
This was reflected by the generation of ROS as reported in several pharmacokinetic studies [58,
59]. GSH is essential for cell survival. Adduct formation with GSH causes GSH depletion,
leading to accumulation of ROS resulting in oxidative mitochondrial damage, ultimately
causing cell death [60]. Although the exact role of GSH depletion in apoptosis is still contro-
versial, it remains an early hallmark in the progression of cell death in numerous cell types [61].
Therefore, adduct formation between SHetA2 and GSH could be vital to the induction of
apoptosis, as indicated by the ROS generation. However, further studies suggested that ROS
generation appeared to be a consequence of, and not a cause for, mitochondrial swelling and
apoptosis induced by SHetA2 treatment [7, 9]. Addition of GSH did not attenuate SHetA2-
induced apoptosis [55]. It was also noted that the cellular GSH level was in the μM range, while
μM SHetA2 is sufficient to kill cells, indicating that GSH depletion and ROS accumulation are
not the only mechanisms of action. These findings suggest that SHetA2 probably acts through
several mechanisms of action to bring about its apoptotic effect, along with other anticancer
activities, such as cell cycle arrest and induction of differentiation (Table 4).
6.2. Induction of cell-cycle arrest and differentiation
Apart from apoptosis, SHetA2 repression of NF-kB expression also initiates a series of events
that can lead to cell-cycle arrest and cell differentiation. SHetA2-induced Cyclin D1 degrada-
tion in both Caki-1 renal cancer and normal HK-2 cell lines results in the accumulation of cells
in the G0-G1 phase [7]. Cyclin D1 degradation alone has shown to be sufficient in inducing G1
cell cycle arrest [11]. Cyclin D1 transcription can be induced by NF-kB through multiple NF-
kB-binding sites in the Cyclin D1 promoter, which is consistent with the observed down
regulation of Cyclin D1. Also, SHetA2 can induce cellular differentiation in kidney [7], as well
as in ovarian cancer organotypic cultures and xenografts [5]. Treatment of these cancer cells
shows that 1 μM SHetA2 is sufficient to reverse the cancerous phenotype depending on the
status of the cells. However, at higher concentrations of SHetA2, apoptosis would dominate
over differentiation. The mechanism for differentiation induction is likely to be associated with
the upregulation of E-Cadherin in renal cancer cells observed with the repression of NF-kB [7].
Decrease or loss of nuclear E-Cadherin expression is associated with poor prognosis in kidney
cancer, as it confers the ability to migrate and invade [64]. Therefore, up-regulation or resto-
ration of E-Cadherin’s function has been one of the therapeutic goals for anticancer treatments.
6.3. Antiangiogenic activity
Microarray analysis have suggested that SHetA2 treatment results in significant up-regulation
of thrombospondin-4 (TSP-4), and down-regulation of thymidine phosphorylase (TP) in A2780
ovarian cancer cells. TSP-4 and TP protein levels followed those of the mRNA. TSP-4 was
hypothesized to be antiangiogenic due to the presence of type-III repeats which is also found
in TSP-1. The type-III repeats in TSP-1 has been reported to inhibit the binding of fibroblast
growth factor-2 to endothelial cells, a process that leads to endothelial cell proliferation in vitro
[65]. As for TP, it has found to be angiogenic through its ability to convert thymidine to thymine
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and the angiogenic 2-deoxy-D-ribose-1-phosphate, as well as its metabolite, deoxy-D-ribose.
Protein levels of the angiogenic vascular endothelial growth factor A (VEGF) was also found
to be downregulated despite its up-regulated mRNA level upon SHetA2 treatment. Interest-
ingly, both mRNA and protein levels of the angiogenic basic fibroblast growth factor (bFGF)
were also up-regulated, but its effect was deemed limited due to brief up-regulation of the
gene only after hours of treatment with high concentration of SHetA2 [12]. Hence, the net effect
of SHetA2 on these various proteins is antiangiogenic, and is supported by the decrease of
endothelial tube formation observed in a number of cancer cell lines as well as human umbilical
vascular endothelial cells (HUVECs) [12].
Figure 9. Structural comparison of SHetA2 and its metabolite with sorafenib and linifanib.
6.4. Kinase inhibitory activity
SHetA2 is also being evaluated for its ability to inhibit kinase activity based on its structural
similarity to sorafenib and linifanib (Figure 9) [63]. Sorafenib is an FDA approved diarylurea
multikinase inhibitor that inhibits tumor growth, while linifanib is a KIT-3 kinase inhibitor [66,
67]. All three compounds consist of a three atom urea or thiourea linker between two aromatic
rings, of which this structural conformation is found to be vital for the formation of key H-
bonds within the binding pockets of several kinases, including B-Raf, BCR-ABL, and KIT [63].
Upon evaluation with 442 different human kinases, SHetA2(Figure 9) has exhibited good
binding affinity for KIT kinase (binding constant, Kd = 820 nM). This indicates that SHetA2 is
a potential candidate for kinase inhibitor development. More importantly, one of the metab-
olites of SHetA2 (Figure 9, 25) has also shown comparable binding affinity for KIT kinase (Kd
= 1200 nM) [63]. This suggests that other metabolites of SHetA2 may also be active, which could
have acted via different mechanisms of action and contributed to the various anticancer effects
observed, making it a versatile chemotherapeutic agent.
7. Metabolism of SHetA2
Using liquid chromatography and tandem mass spectroscopy, four GSH adducts were
identified along with four mono- and dihydroxylated SHetA2 metabolites [58]. At least one of
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these metabolites (Figure 9, 25) has been deemed active against KIT kinase as mentioned
earlier. Apart from the hydroxylated metabolites, other metabolites of SHetA2 were also
detected in vivo [58, 59]. These metabolites may be produced upon formation of GSH adducts.
The proposed mechanism for the formation of GSH adduct is shown in Figure 10. Subse-
quently, the GSH adduct could undergo further reactions that may result in the cleavage of the
Figure 10. Proposed mechanism for the GSH adduct formation of SHetA2.
Figure 11. Proposed mechanism for the formation of metabolites following the formation of GSH adducts.
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thiourea linker, yielding two metabolites that were also detected in vivo [58]. The proposed
mechanism for the formation of these metabolites is shown in Figure 11.
Given that ShetA2 has several mechanisms of action involving various cellular targets, these
findings suggest the possibility for SHetA2 to be metabolized into several active metabolites,
each targeting a different molecular pathway. This is further supported by a recent in vivo study
where the monohydroxy SHetA2 (25) was found to be the major metabolite of SHetA2 in rat
plasma, and it was detected at a much higher concentration than the parent compound after
oral and intravenous administration [13].
8. Pharmacokinetics
Pharmacokinetic studies using HPLC/UV of SHetA2 in mice(Table 5) have shown that
pharmacokinetic profile of this compound is favorable for future development [59].
  PK  SHetA2 
1 Oral bioavailability at 20 mg/kg  15% 
  Oral bioavailability at 60 mg/kg  19% 
2 Urinary excretion (%)  Not reported 
3 Bound to mouse and human plasma proteins at μM concentrations  99.3–99.5% 
4 Total body clearance (L/h/kg)  1.8 
5 Volume distribution (L/kg) at steady state (Vdss)  20.8 
6 Half-life in mouse plasma  12.7 h 
  Half-life in the mouse  Detectable after 60 h after IV
administration 
  Half-life in human plasma (once a day dosing proposed)  12 h 
7 Peak time (plasma concentrations of 10 μM following i.v. bolus dose) 5 min 
8 Peak concentration (IV 20 mg/kg dose of SHetA2 to mice)  10 μM after 5 min 
  Maxima mean plasma concentration in the mouse (PO)  0.79 μM at 2 h 
    2.35 μM at 3 h 
Table 5. Pharmacokinetic data of SHetA2 [59].
9. Possible clinical applications
SHetA2 is now in Phase-0 clinical trial for ovarian cancer chemoprevention. However, since it
inhibits growth of most cancers in vitro and in vivo, it may potentially be used for the prevention
and treatment of other cancers which are listed in Table 6.
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Cancer type Findings References
Ovarian cancer G1-phase cell cycle arrest through cyclin D1 degradation and apoptosis.
Reduced cell survival, and increased sensitivity to TRAIL- and TNFα-
induced apoptosis. Induced glandular differentiation reversed cancerous
phenotype.
[14]
Uterine cancer
• Endometrial
carcinoma (HEC-1-A)
• MMT (MES-SA)
• uterine sarcoma (SK-UT-1)
SHetA2 decreased survival of all three cell lines, but did not increase
sensitivities of cell lines to chemotherapeutic drugs.
[57]
Lung cancer (NSCLC) Increased sensitivity to TRAIL-induced apoptosis through modulation
of c-FLIP and upregulation of DR5. Inhibits growth, triggers ER stress.
[5, 49]
Head and neck cancer
(HNSCC) 
Apoptosis in 8 HNSCC cell lines. [32]
Cervical cancer Growth inhibition by micromolar concentrations. [5]
Kidney cancer Induced G1 cell cycle arrest in Caki-1 and normal HK-2 cell lines;
decreased cyclin D expression; induces apoptosis.
[7]
Table 6. Possible anti-cancer clinical applications of SHetA2 and documented results from different studies.
10. Conclusion
SHetA2 has exhibited anticancer activity in 60 NCI cancer cells and has shown favorable re-
sults in inhibiting various types of cancer growth in vivo, particularly ovarian cancer. It ex-
erts various chemopreventive and chemotherapeutic activities through its ability to induce
apoptosis and Differentiation, and inhibit angiogenesis and cell growth. It promotes mito-
chondrial swelling and mitophagy leading to apoptosis of cancer cells, while sparing normal
cells. Once the targets are validated, tweaking of existing Flex-Hets or synthesis of newer re-
lated analogs may offer greater specificity and improved anticancer activity. Preclinical stud-
ies in animals have shown that SHetA2 has high efficacy with minimal toxicity and has a
good pharmacokinetic profile. This provides the foundation for developing a novel class of
more effective, chemo-preventive and anticancer drugs with a better therapeutic window.
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